Your browser doesn't support javascript.
loading
Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma.
Navarro, Natalia; Molist, Carla; Sansa-Girona, Júlia; Zarzosa, Patricia; Gallo-Oller, Gabriel; Pons, Guillem; Magdaleno, Ainara; Guillén, Gabriela; Hladun, Raquel; Garrido, Marta; Segura, Miguel F; Hontecillas-Prieto, Lourdes; de Álava, Enrique; Ponsati, Berta; Fernández-Carneado, Jimena; Almazán-Moga, Ana; Vallès-Miret, Mariona; Farrera-Sinfreu, Josep; de Toledo, Josep Sánchez; Moreno, Lucas; Gallego, Soledad; Roma, Josep.
Afiliação
  • Navarro N; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Molist C; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Sansa-Girona J; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Zarzosa P; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Gallo-Oller G; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Pons G; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Magdaleno A; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Guillén G; Pediatric Surgery Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Hladun R; Pediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Garrido M; Pathology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Segura MF; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Hontecillas-Prieto L; Institute of Biomedicine of Seville (IBiS), Hospital Universitario Virgen del Rocío/CSIC, University of Seville/CIBERONC, Seville, Spain.
  • de Álava E; Institute of Biomedicine of Seville (IBiS), Hospital Universitario Virgen del Rocío/CSIC, University of Seville/CIBERONC, Seville, Spain.
  • Ponsati B; Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville, Spain.
  • Fernández-Carneado J; BCN Peptides, Pol. Ind. Els Vinyets Els Fogars II, Sant Quintí de Mediona, Barcelona, Spain.
  • Almazán-Moga A; BCN Peptides, Pol. Ind. Els Vinyets Els Fogars II, Sant Quintí de Mediona, Barcelona, Spain.
  • Vallès-Miret M; BCN Peptides, Pol. Ind. Els Vinyets Els Fogars II, Sant Quintí de Mediona, Barcelona, Spain.
  • Farrera-Sinfreu J; BCN Peptides, Pol. Ind. Els Vinyets Els Fogars II, Sant Quintí de Mediona, Barcelona, Spain.
  • de Toledo JS; BCN Peptides, Pol. Ind. Els Vinyets Els Fogars II, Sant Quintí de Mediona, Barcelona, Spain.
  • Moreno L; Laboratory of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Gallego S; Pediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Roma J; Pediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Cell Mol Life Sci ; 79(11): 546, 2022 Oct 11.
Article em En | MEDLINE | ID: mdl-36221013
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiossarcoma / Neuroblastoma Limite: Humans Idioma: En Revista: Cell Mol Life Sci Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiossarcoma / Neuroblastoma Limite: Humans Idioma: En Revista: Cell Mol Life Sci Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha